: Triple-negative breast cancer (TNBC) is the most aggressive subtype of mammary carcinoma. Here, we describe a case of an 81-year-old female diagnosed with ductal triple negative breast cancer with a germline pathogenic variant in BReast CAncer gene2 (BRCA2). Genetic testing also revealed the presence of four somatic mutations in the ephrin type-A receptor 3 (EphA3), TP53, BRCA1-associated protein (BAP1), and MYB genes. The BRCA2, TP53, and BAP1 gene mutations are highly predictive of a defective homologous recombination repair system and subsequent chromosomal instability in this patient. Coherently, the patient displayed a strong homologous recombination deficiency signature and high tumor mutational burden status, which are generally associated with increased probability of immune neoantigens formation and presentation, and with tumor immunogenicity. Analysis of immune checkpoint revealed high expression of programmed cell death ligand 1 (PD-L1), programmed cell death ligand 2 (PD-L2), programmed death 1 (PD1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), suggesting that the patient might likely benefit from immunotherapies. Altogether, these findings support an unveiled link between BRCA2 inactivation, HR deficiency and increased expression of immune checkpoints in TNBC. This clinical case highlights the importance of screening TNBC patients for genetic mutations and TMB biomarkers in order to predict the potential efficacy of immunotherapy.

Han, Y., Rovella, V., Smirnov, A., Buonomo, O.c., Sica, G., G:, M., et al. (2023). A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient, 9, 1-9 [10.1038/s41420-023-01651-3].

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

Han, Yuyi;Rovella, Valentina;Smirnov, Artem;Buonomo, Oreste Claudio;Sica;Perretta, Tommaso;Candi, Eleonora;Bernassola, Francesca
2023-10-09

Abstract

: Triple-negative breast cancer (TNBC) is the most aggressive subtype of mammary carcinoma. Here, we describe a case of an 81-year-old female diagnosed with ductal triple negative breast cancer with a germline pathogenic variant in BReast CAncer gene2 (BRCA2). Genetic testing also revealed the presence of four somatic mutations in the ephrin type-A receptor 3 (EphA3), TP53, BRCA1-associated protein (BAP1), and MYB genes. The BRCA2, TP53, and BAP1 gene mutations are highly predictive of a defective homologous recombination repair system and subsequent chromosomal instability in this patient. Coherently, the patient displayed a strong homologous recombination deficiency signature and high tumor mutational burden status, which are generally associated with increased probability of immune neoantigens formation and presentation, and with tumor immunogenicity. Analysis of immune checkpoint revealed high expression of programmed cell death ligand 1 (PD-L1), programmed cell death ligand 2 (PD-L2), programmed death 1 (PD1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), suggesting that the patient might likely benefit from immunotherapies. Altogether, these findings support an unveiled link between BRCA2 inactivation, HR deficiency and increased expression of immune checkpoints in TNBC. This clinical case highlights the importance of screening TNBC patients for genetic mutations and TMB biomarkers in order to predict the potential efficacy of immunotherapy.
9-ott-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/18
English
Han, Y., Rovella, V., Smirnov, A., Buonomo, O.c., Sica, G., G:, M., et al. (2023). A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient, 9, 1-9 [10.1038/s41420-023-01651-3].
Han, Y; Rovella, V; Smirnov, A; Buonomo, Oc; Sica, G; G:, M; Alessandro, ; Perretta, T; Shi, Y; Woodmsith, J; Bischof, J; Melino, G; Candi, E; Bernassola, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
A BRCA.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright degli autori
Dimensione 2.22 MB
Formato Adobe PDF
2.22 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/341183
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact